Buy & Sell Vertex Pharmaceuticals Incorporated (VRTX) – Vertex Pharmaceuticals Incorporated Price Today
Key Stats
- $111.45BMarket Cap
- HealthSector
- -13.24%3M Drawdown
- $106.87BEnterprise Value
- -Dividend Yield
- 89% Buy | 11% SellTrading Activity
- 96 daysTypical Hold Time
Vertex Pharmaceuticals Incorporated (VRTX) is currently valued at a market capitalization of $111.45B, with an enterprise value of $106.87B. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $509.5, highlighting its annual price range. Over the past three months, Vertex Pharmaceuticals Incorporated has recorded a drawdown of -13.24%, reflecting recent price volatility. Vertex Pharmaceuticals Incorporated offers a dividend yield of -. On average, investors hold Vertex Pharmaceuticals Incorporated for approximately 96 days, indicating typical investor behavior on the platform.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
